Abstract
Summary
Characteristics of patients starting oral bisphosphonate therapy changed over time, reflecting trends in osteoporosis management (e.g., new drugs to market), and general healthcare delivery (e.g., benzodiazepine use declined, statin use increased). When designing studies that examine osteoporosis drug effects, potential time-related biases must be considered.
Introduction
To describe the type of oral bisphosphonate initiated and characteristics of patients starting oral bisphosphonate therapy over time.
Methods
We identified community-dwelling older adults (ages ≥ 66 years) initiating oral bisphosphonate therapy from April 1996 to March 2016 (1996 to 2015 fiscal years) using healthcare administrative data in Ontario. Patients with conditions other than osteoporosis that may impact bisphosphonate prescribing were excluded. The bisphosphonate initiated and patient characteristics were summarized by fiscal year and stratified by sex.
Results
We identified 560,817 eligible patients (81% women). Most patients initiated cyclical etidronate from 1996 until 2005, and then weekly regimens became dominant. In 2008, risedronate became the main oral bisphosphonate (46% risedronate, 43% alendronate, 11% etidronate); with its use increasing after availability of monthly and delayed-release risedronate formulations. In 2015, 71% of patients started risedronate, 28% started alendronate, and less than 2% started etidronate. Characteristics of patients changed over time, reflecting changes in osteoporosis management and general healthcare delivery. Over time, a larger proportion of men (9% to 28%) and patients with diabetes (women 10% to 17%, men 14% to 22%) initiated therapy; benzodiazepine (women 22% to 13%, men 20% to 10%) and estrogen-based hormone replacement therapy (12% to 15% of women 1996–2002 to 3% since 2008) decreased, while statin use increased (women 15% to 39%, men 14% to 52%).
Conclusions
The characteristics of patients starting oral bisphosphonate therapy have changed over time. Consideration must be given to these time trends when designing studies that examine osteoporosis drug effects.
Similar content being viewed by others
References
Cadarette SM, Carney G, Baek D, Gunrai N, Paterson JM, Dormuth CR (2012) Osteoporosis medication prescribing in British Columbia and Ontario: impact of public drug coverage. Osteoporos Int 23:1475–1480. https://doi.org/10.1007/s00198-011-1771-2
Burden AM, Tadrous M, Calzavara A, Cadarette SM (2015) Uptake and characteristics of zoledronic acid and denosumab patients and physicians in Ontario, Canada: impact of drug formulary access. Osteoporos Int 26:1525–1533. https://doi.org/10.1007/s00198-014-3023-8
Drug Programs Policy and Strategy Branch, Ontario Public Drug Programs,Ministry of Health and Long-Term Care (2018) Ontario drug benefit formulary/comparative drug index, Edition 43. http://www.health.gov.on.ca/en/pro/programs/drugs/formulary43/edition_43.pdf. Accessed 23 July 2018
Papaioannou A, Morin S, Cheung AM, Atkinson S, Brown JP, Feldman S, Hanley DA, Hodsman A, Jamal SA, Kaiser SM, Kvern B, Siminoski K, Leslie WD, for the Scientific Advisory Council of Osteoporosis Canada (2010) 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. CMAJ 182:1864–1873. https://doi.org/10.1503/cmaj.100771
Jandoc R, Mamdani M, Levesque LE, Cadarette SM (2016) Urban–rural differences in the uptake of new oral bisphosphonate formulations. Arch Osteoporosis 11(11). https://doi.org/10.1007/s11657-016-0261-8
Fraser LA, Albaum JM, Tadrous M, Burden AM, Shariff SZ, Cadarette SM (2015) Patterns of use for brand-name versus generic oral bisphosphonate drugs in Ontario over a 13-year period: a descriptive study. CMAJ Open 3(1):E91–E95. https://doi.org/10.9778/cmajo.20140090
Schneeweiss S, Gagne JJ, Glynn RJ, Ruhl M, Rassen JA (2011) Assessing the comparative effectiveness of newly marketed medications: methodological challenges and implications for drug development. Clin Pharmacol Ther 90(6):777–790. https://doi.org/10.1038/clpt.2011.235
Reams BD, O’Malley CD, Critchlow CW, Lauffenburger JC, Brookhart MA (2014) Changing patterns of use of osteoporosis medications in the years after launch: implications for comparative effectiveness research. Pharmacoepidemiol Drug Saf 23:251–260. https://doi.org/10.1002/pds.3545
Cadarette SM, Levésque L, Mamdani M et al (2013) Comparison of orally administered bisphosphonate drugs in reducing the risk of hip fracture in older adults: a population-based cohort study. CMAJ Open 1(3):E97–E105. https://doi.org/10.9778/cmajo.20130036
Health Canada (2018) Notice of compliance (NOC) online query. https://health-products.canada.ca/noc-ac/index-eng.jsp. Accessed 20 August 2018
U.S. Food and Drug Administration (2010) FDA drug safety communication: safety update for osteoporosis drugs, bisphosphonates, and atypical fractures. https://www.fda.gov/drugs/drugsafety/ucm229009.htm. Accessed 23 October 2018
Health Canada (2011) Bisphosphonate osteoporosis drugs (Aclasta, Actonel, Didrocal, Fosamax, Fosavance): small but increased risk of unusual thigh bone fractures. http://www.healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2011/13569a-eng.php?_ga=1.85354845.556616913.1404224643. Accessed 23 October 2018
Kim SC, Kim DH, Mogun H, Eddings W, Polinski JM, Franklin JM, Solomon DH (2018) Impact of the U.S. Food and Drug Administration’s safety-related announcements on the use of bisphosphonates after hip fracture. J Bone Miner Res 31:1536–1540. https://doi.org/10.1002/jbmr.2832
Jha S, Wang Z, Laucis N, Bhattacharyya T (2015) Trends in media reports, oral bisphosphonate prescriptions, and hip fractures 1996-2012: an ecologic analysis. J Bone Miner Res 30(12):2179–2187
Sambrook PN, Chen JS, Simpson JM, March LM (2010) Impact of adverse news media on prescriptions for osteoporosis: effect on fractures and mortality. Med J Aust 193:154–156
Statistics Canada (1998) Profile of Federal Electoral Districts (1996 representation order), 1996 census. Statistics Canada Catalogue 95F0180XDB96001. Accessed 8 January 2019
Statistics Canada (2002) Population and dwelling counts, for provinces and territories, census divisions and dissemination areas, 2001 census - 100% data. Statistics Canada Catalogue 93F0050XCB2001010. Accessed 8 January 2019
Statistics Canada (2007) Profile of age and sex for Canada, provinces, territories, census divisions and census subdivisions, 2006 census. Statistics Canada Catalogue 94–575-XCB2006001. Accessed 8 January 2019
Statistics Canada (2012) Census profile - age and sex for Canada, provinces, territories, census divisions and census subdivisions, 2011 census. Statistics Canada Catalogue 98–311-XCB2011006. Accessed 8 January 2019
Cadarette SM, Katz JN, Brookhart MA, Stümer T, Stedman MR, Solomon DH (2008) Relative effectiveness of osteoporosis drugs for preventing nonvertebral fracture. Ann Intern Med 148:637–646. https://doi.org/10.7326/0003-4819-148-9-200805060-00003
Van der Velde RY, Wyers CE, Teesselink E et al (2017) Trends in oral anti-osteoporosis drug prescription in the United Kingdom between 1990 and 2012: variation by age, sex, geographic location and ethnicity. Bone 94:50–55. https://doi.org/10.1016/j.bone.2016.10.013
Allain H, Bentué-Ferrer D, Polard E, Akwa Y, Patat A (2005) Postural instability and consequent falls and hip fractures associated with use of hypnotics in the elderly: a comparative review. Drugs Aging 22:749–765. https://doi.org/10.2165/00002512-200522090-00004
Pottie K, Thompson W, Davies S, Grenier J, Sadowski CA, Welch V, Holbrook A, Boyd C, Swenson R, Ma A, Farrell B (2018) Deprescribing benzodiazepine receptor agonists: evidence-based clinical practice guideline. Can Fam Physician 64:339–351
American Geriatrics Society 2015 Beers Criteria Update Expert Panel (2015) American Geriatrics Society 2015 updated beers criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc 63:2227–2246. https://doi.org/10.1111/jgs.13702
O’Neil CK, Hanlon JT, Marcum ZA (2012) Adverse effects of analgesics commonly used by older adults with osteoarthritis: focus on non-opioid and opioid analgesics. Am J Geriatr Pharmacother 10:331–342. https://doi.org/10.1016/j.amjopharm.2012.09.004
Busse JW, Craigie S, Juurlink DN, Buckley DN, Wang L, Couban RJ, Agoritsas T, Akl EA, Carrasco-Labra A, Cooper L, Cull C, da Costa BR, Frank JW, Grant G, Iorio A, Persaud N, Stern S, Tugwell P, Vandvik PO, Guyatt GH (2017) Guideline for opioid therapy and chronic noncancer pain. CMAJ 189:E659–E666. https://doi.org/10.1503/cmaj.170363
Dowell D, Haegerich TM, Chou R (2016) CDC guideline for prescribing opioids for chronic pain — United States, 2016. MMWR Recomm Rep 65:1–49. https://doi.org/10.15585/mmwr.rr6501e1er
Wright MJ, Proctor DD, Insogna KL, Kerstetter JE (2008) Proton pump-inhibiting drugs, calcium homeostasis, and bone health. Nutr Rev 66:103–108. https://doi.org/10.1111/j.1753-4887.2008.00015.x
Wright MJ, Rebecca RS, Erin GS et al (2010) Inhibiting gastric acid production does not affect intestinal calcium absorption in young, healthy individuals: a randomized, crossover, controlled clinical trial. J Bone Miner Res 25:2205–2211. https://doi.org/10.1002/jbmr.108
Barkun AM, Bardou M, Pham CQ, Martel M (2012) 2012 meta-analysis: critically ill patients at risk of stress-related mucosal bleeding had significantly decreased rates of clinically significant bleeding with PPI prophylaxis compared with H2RA prophylaxis. Am J Gastroenterol 107:507–520. https://doi.org/10.1038/ajg.2011.474
Health Canada Therapeutic Products Directorate (1997) Labeling standard: histamine 2 receptor antagonist for famotidine for OTC use. https://www.canada.ca/content/dam/hc-sc/migration/hc-sc/dhp-mps/alt_formats/hpfb-dgpsa/pdf/prodpharma/famotidi-eng.pdf. Accessed 23 July 2018
Health Canada (2014) Prescription Drug List (PDL): Omeprazole https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/prescription-drug-list/notice-omeprazole.html. Accessed 23 July 2018
Rossouw JE, Anderson GL, Prentice RL, et al (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 17;288(3):321–333
Brown JP, Josse RG (2002) Clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ 167:S1–S34
Paterson JM, Suleiman A, Hux JE, Bell C (2008) How complete are drug history profiles that are based on public drug benefit claims? Can J Clin Pharmacol 15(1):e108–e116
Canadian Institute for Health Information (2016) Drug use among seniors in Canada, 2016. https://www.cihi.ca/sites/default/files/document/drug-use-among-seniors-2016-en-web.pdf. Accessed January 12, 2019. https://www.ices.on.ca/Publications/Journal-Articles/2008/January/How-complete-are-drug-history-profiles-that-are-based-on-public-drug-benefit-claims
Canadian Institute for Health Information (2018) National Ambulatory Care Reporting System Metadata (NACRS). https://www.cihi.ca/en/national-ambulatory-care-reporting-system-metadata. Accessed 23 October 2018
Walker RL, Hennessy DA, Johansen H, Sambell C, Lix L, Quan H (2012) Implementation of ICD-10 in Canada: how has it impacted coded hospital discharge data? BMC Health Serv Res 12:149 https://health-products.canada.ca/noc-ac/index-eng.jsp. Accessed 20 August 2018
Funding
This research was supported, in part, by Canadian Institutes of Health Research Drug Safety and Effectiveness Cross-Disciplinary Training Program Stream 1 Trainee Awards to Kaleen Hayes and Joann Ban. This study was supported by ICES, which is funded by an annual grant from the Ontario Ministry of Health and Long-Term Care (MOHLTC). The opinions, results, and conclusions reported in this paper are those of the authors and are independent from the funding sources. No endorsement by ICES or the Ontario MOHLTC is intended or should be inferred. Parts of this material are based on data and/or information compiled and provided by the Canadian Institutes of Health Information (CIHI). However, the analyses, conclusions, opinions, and statements expressed in the material are those of the author(s) and not necessarily those of CIHI. We thank IMS Brogan Inc. for use of their Drug Information Database. All analyses were completed at the ICES University of Toronto site, supported by the Leslie Dan Faculty of Pharmacy.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
This study was approved by the Research Ethics Boards at Sunnybrook Health Sciences Centre in Toronto and the University of Toronto.
Conflicts of interest
None.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
ESM 1
(DOCX 60.6 kb)
Rights and permissions
About this article
Cite this article
Hayes, K., Ban, J., Athanasiadis, G. et al. Time trends in oral bisphosphonate initiation in Ontario, Canada over 20 years reflect drug policy and healthcare delivery changes. Osteoporos Int 30, 2311–2319 (2019). https://doi.org/10.1007/s00198-019-05061-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00198-019-05061-z